Binding selectivity studies of PKBα using molecular dynamics simulation and free energy calculations

被引:7
作者
Chen, Shi-Feng [1 ]
Cao, Yang [1 ]
Chen, Jiong-Jiong [1 ]
Chen, Jian-Zhong [1 ]
机构
[1] Zhejiang Univ, Coll Pharmaceut Sci, Inst Mat Med, Hangzhou 310058, Zhejiang, Peoples R China
关键词
Binding free energy; Inhibitor; Molecular dynamics simulation; Protein kinase A/PKA; Protein kinase B/PKB; Selectivity; FORCE-FIELD; AKT; INHIBITORS; DISCOVERY; MECHANICS; INSIGHTS; PROGRESS; TARGET; MODEL;
D O I
10.1007/s00894-013-1997-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Designing selective protein kinase B (PKB/Akt) inhibitor is an area of intense research to develop potential anticancer drugs. In the present study, the molecular basis governing PKB-selective inhibition has been investigated using molecular dynamics simulation. The binding free energies calculated by MM/PBSA gave a good correlation with the experimental biological activity and a good explanation of the activity difference of the studied inhibitors. The decomposition of free energies by MM/GBSA indicates that the ethyl group on pyrrolo[2,3-d]pyrimidine ring of inhibitor Lig1 (N-{[(3S)-3-amino-1-(5-ethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrolidin-3-yl]-methyl}-2,4-difluoro-benzamide) is an important contributor to its PKB alpha selectivity due to its hydrophobic interaction with the side chain of Thr291 in PKB alpha. The substituted groups on the pyrrolidine ring of Lig1 also show a strong tendency to mediate protein-ligand interactions through the hydrogen bonds formed between the amino or amide groups of Lig1 and the carboxyl O atoms of Glu234, Glu278, and Asp292 of PKB alpha. It was reported that there are only three key amino acid differences between PKB alpha (Thr211, Ala230, Met281) and PKA (Val104, Val123, Leu173) within the clefts of ATP-binding sites. These differences propel a drastic conformational change in PKA, weakening its binding interactions with inhibitor. The impact was also confirmed by MD simulated interaction modes of inhibitor binding to PKB alpha mutants with the in silico mutations of the three key amino acids, respectively. We expect that the results obtained here could be useful for future rational design of specific ATP-competitive inhibitors of PKB alpha.
引用
收藏
页码:5097 / 5112
页数:16
相关论文
共 39 条
  • [1] Alexey O., 2004, PROTEINS, V55, P383
  • [2] [Anonymous], 2010, AMBER 2011
  • [3] [Anonymous], 2012, AMBER 2012
  • [4] The Akt/PKB family of protein kinases: A review of small molecule inhibitors and progress towards target validation
    Barnett, SF
    Bilodeau, MT
    Lindsley, CW
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (02) : 109 - 125
  • [5] A WELL-BEHAVED ELECTROSTATIC POTENTIAL BASED METHOD USING CHARGE RESTRAINTS FOR DERIVING ATOMIC CHARGES - THE RESP MODEL
    BAYLY, CI
    CIEPLAK, P
    CORNELL, WD
    KOLLMAN, PA
    [J]. JOURNAL OF PHYSICAL CHEMISTRY, 1993, 97 (40) : 10269 - 10280
  • [6] Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors
    Bencsik, Josef R.
    Xiao, Dengming
    Blake, James F.
    Kallan, Nicholas C.
    Mitchell, Ian S.
    Spencer, Keith L.
    Xu, Rui
    Gloor, Susan L.
    Martinson, Matthew
    Risom, Tyler
    Woessner, Richard D.
    Dizon, Faith
    Wu, Wen-I
    Vigers, Guy P. A.
    Brandhuber, Barbara J.
    Skelton, Nicholas J.
    Prior, Wei Wei
    Murray, Lesley J.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (23) : 7037 - 7041
  • [7] MOLECULAR-DYNAMICS WITH COUPLING TO AN EXTERNAL BATH
    BERENDSEN, HJC
    POSTMA, JPM
    VANGUNSTEREN, WF
    DINOLA, A
    HAAK, JR
    [J]. JOURNAL OF CHEMICAL PHYSICS, 1984, 81 (08) : 3684 - 3690
  • [8] Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors
    Blake, James F.
    Xu, Rui
    Bencsik, Josef R.
    Xiao, Dengming
    Kallan, Nicholas C.
    Schlachter, Stephen
    Mitchell, Ian S.
    Spencer, Keith L.
    Banka, Anna L.
    Wallace, Eli M.
    Gloor, Susan L.
    Martinson, Matthew
    Woessner, Richard D.
    Vigers, Guy P. A.
    Brandhuber, Barbara J.
    Liang, Jun
    Safina, Brian S.
    Li, Jun
    Zhang, Birong
    Chabot, Christine
    Do, Steven
    Lee, Leslie
    Oeh, Jason
    Sampath, Deepak
    Lee, Brian B.
    Lin, Kui
    Liederer, Bianca M.
    Skelton, Nicholas J.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (18) : 8110 - 8127
  • [9] Studying the mechanism that enables paullones to selectively inhibit glycogen synthase kinase 3 rather than cyclin-dependent kinase 5 by molecular dynamics simulations and free-energy calculations
    Chen, Quan
    Cui, Wei
    Cheng, Yuanhua
    Zhang, Fushi
    Ji, Mingjuan
    [J]. JOURNAL OF MOLECULAR MODELING, 2011, 17 (04) : 795 - 803
  • [10] Cheng GZ, 2008, CURR CANCER DRUG TAR, V8, P2